In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers. They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies. Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease. Key clinical takeaways: Unlike NETs, EP-NECs are poorly differentiated, high-grade, aggressive, and fast-growing cancers, with a need for more effective treatments While there remains a medical need for effective treatment of EP-NECs, clinical studies with DLL3-targeted agents show promise Accessing a support network can provide emotional reinforcement and information for patients and their care partners You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/net-connect/programmes/ep-nec-diagnosis-treatment-support/?media=0 Or watch on YouTube: https://youtu.be/nfng2s3jSw8 Follow us on social media: LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true X:https://x.com/net_connectinfo This podcast is supported by an Independent Education Grant from Boehringer Ingelheim. This podcast is developed by cor2ed.com Published in November 2025 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related